# Remote Monitored Systems to acquire 100% of Pharm2Farm Limited

- Link: https://www.directorstalkinterviews.com/remote-monitored-systems-to-acquire-100-of-pharm2farm-limited/412854433
- Published: 2020-08-24T07:16:16+01:00
- Author: Amilia Stone

**Remote Monitored Systems plc** ([LON:RMS](https://www.directorstalkinterviews.com/company/remote-monitored-systems-plc/rms.l))
has announce that further to the announcement of 17 July 2020, it has signed a binding
Share Purchase Agreement for the acquisition of 100% of the share capital of Pharm2Farm
Limited. Completion of the Acquisition is subject to regulatory and RMS shareholder
approval.  The Acquisition will be satisfied by the issue of 600,000,000 new ordinary
shares of 0.01 pence each in the capital of the Company, equating to approximately
£2,370,000 based on RMS’s closing share price on 20 August 2020.

The vendors of P2F are Braveheart Investment Group plc (51.72%) and Dr. Gareth Cave,
the founder of P2F (48.28%) who will receive 310,354,815 and 289,645,185 Consideration
Shares respectively. On completion of the Acquisition, Braveheart will hold 509,992,405
ordinary shares, representing 37.12% of the enlarged share capital of the Company.
Dr. Gareth Cave will own 21.08% of the enlarged share capital of the Company.

The Vendors are presumed to be acting in concert and as they will own more than 
50%, and Braveheart will own more than 30%, of RMS on completion of the Acquisition,
the Acquisition is conditional upon a waiver being granted by the UK Panel on Takeovers
and Mergers (the “Panel”) from the obligation of Braveheart and the Vendor concert
party, to make a mandatory offer for the Company under Rule 9 of the City Code. 
Such waiver, if granted, will be subject to the Company obtaining approval of independent
shareholders of RMS at a General Meeting. 

It is also intended that upon completion of the Acquisition, the Company, the Vendors
and SP Angel Corporate Finance LLP, as the Company’s nominated adviser, enter into
a relationship agreement.

A circular setting out further details of the Acquisition, the relationship agreement
and the Rule 9 Waiver (including details in respect of any other parties deemed 
to be acting in concert with the Vendors), and giving notice of the General Meeting
to approve these proposals will be sent to the Company’s shareholders as soon as
reasonably practicable.

**Related Party Transaction**

Braveheart, as a substantial shareholder of the Company, is considered to be a “
related party” as defined under the AIM Rules and accordingly, the proposed purchase
of Braveheart’s shareholding in P2F as part of the Acquisition, constitutes a related
party transaction for the purposes of Rule 13 of the AIM Rules.

The Directors independent of the Acquisition, being Paul Ryan (Non‐Executive Chairman)
and John Richardson (Chief Operating Officer) consider, having consulted with the
Company’s nominated adviser, that the terms of the Acquisition are fair and reasonable
insofar as the Company’s shareholders are concerned.

A further announcement will be made in due course.

**About Pharm2Farm**

Pharm2farm uses a patented process for producing and functionalising nanoparticles
for various applications including human, animal and crop health. Since, Braveheart
Investment Group acquired an interest in Pharm2Farm, the team has moved into a new
facility in MediCity Nottingham and more than doubled nanoparticle production capacity.
Pharm2Farm’s strategy is focused on two markets:

**_Crop nutrition:_** Pharm2Farm has already received orders from key distributors
in the UK and South Korea for its unique crop nutrition products. Pharm2Farm is 
specifically targeting the growing global hydroponics market where its water-soluble
nutrients with high bioavailability have a clear competitive advantage. A number
of trials are underway to explore further applications of Pharm2Farm formulations

**_Anti-viral Face Mask_**: Pharm2Farm is developing a nanotechnology enabled anti-
viral face mask. Proof of concept and the design of a prototype is currently underway
and expected to be completed by the end of the year. Once proven, Pharm2Farm will
commence the commercial manufacture of masks in the UK.

P2F had unaudited revenues of £11,979 and profit of £4,292 for the seven month period
ending 31 March 2020.

Remote Monitored Systems considers that the opportunity to acquire and unite the
two shareholdings of P2F, a business operating in two vital sectors and on the brink
of near term growth, will lead to significant enhancement of shareholder value for
RMS shareholders.

Share on:
